Neurofilament Heavy polypeptide CpG island methylation associates with prognosis of renal cell carcinoma and prediction of antivascular endothelial growth factor therapy response

Cancer medicine

Volumn 3, Issue 2, 2014, Pages 300-309

  Dubrowinskaja, Natalia ^a   Gebauer, Kai ^a   Peters, Inga ^a   Hennenlotter, Jörg ^a   Abbas, Mahmoud ^a   Scherer, Ralph ^a   Tezval, Hossein ^a   Merseburger, Axel S ^a   Stenzl, Arnulf ^a   Grünwald, Viktor ^a   Kuczyk, Markus A ^a   Serth, Jürgen ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

Methylation; risk assessment; translational research; urological oncology

Indexed keywords

ANGIOGENESIS INHIBITOR; ENDOTHELIAL CELL GROWTH FACTOR; NEUROFILAMENT PROTEIN; NEUROFILAMENT PROTEIN H;

AGED; ANTAGONISTS AND INHIBITORS; BLOOD; CARCINOMA, RENAL CELL; COHORT ANALYSIS; CPG ISLAND; CROSS-SECTIONAL STUDY; DNA METHYLATION; FEMALE; GENETICS; HUMAN; KIDNEY NEOPLASMS; MALE; METABOLISM; PROGNOSIS; PROMOTER REGION; RISK ASSESSMENT; TUMOR CELL LINE; VASCULARIZATION;

AGED; ANGIOGENESIS INHIBITORS; CARCINOMA, RENAL CELL; CELL LINE, TUMOR; COHORT STUDIES; CPG ISLANDS; CROSS-SECTIONAL STUDIES; DNA METHYLATION; ENDOTHELIAL GROWTH FACTORS; FEMALE; HUMANS; KIDNEY NEOPLASMS; MALE; NEUROFILAMENT PROTEINS; PROGNOSIS; PROMOTER REGIONS, GENETIC; RISK ASSESSMENT;

EID: 84911925221     PISSN: None     EISSN: 20457634     Source Type: Journal    
DOI: 10.1002/cam4.181     Document Type: Article

References (0)